Advertisement
Advertisement
CLDI
Calidi Biotherapeutics Inc - Class A
1.44
USD-0.29
-16.76%
Dec 18, 15:59 UTC -5
Closed
...
Calidi Biotherapeutics Inc - Class A Profile
About
Info & Links
CEO
Allan J. Camaisa
Headquarters
SAN DIEGO, CA 92121, UNITED STATES
Industry
Sector
Website
Auditor
Marcum llp
Share holders
1
Employees
41
Calidi Biotherapeutics Inc - Class A Statistics
Valuation Measures
Market Capitalization2
28.51M
Enterprise Value
32.31M
Enterprise Value/EBITDA(ttm)
-1.23
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
333.38%
Return on Assets(ttm)
-344.45%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-26.30M
Net Income Available to Common(ttm)
-27.95M
Diluted EPS(ttm)
--
Share Statistics
Beta (5Y Monthly)
1.05
52-Week Change
-92.65%
S&P 500 52-Week Change
23.87%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
13.08M
Dividend Yield
0.00%
Float4
9.90M
% Held by Insiders
24.28%
% Held by Institutions
12.53%
Balance Sheet
Total Cash(mrq)
1.90M
Total Cash Per Share(mrq)
0.15
Total Debt(mrq)
5.70M
Total Debt/Equity(mrq)
-58.15%
Current Ratio(mrq)
0.19%
Quick Ratio(mrq)
0.19%
Book Value Per Share(mrq)
-1.05
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.82
Free Cash Flow(ytd)
-14.28M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement